0001209191-23-048222.txt : 20230905
0001209191-23-048222.hdr.sgml : 20230905
20230905173307
ACCESSION NUMBER: 0001209191-23-048222
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230901
FILED AS OF DATE: 20230905
DATE AS OF CHANGE: 20230905
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shah Pratik
CENTRAL INDEX KEY: 0001580787
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40288
FILM NUMBER: 231237072
MAIL ADDRESS:
STREET 1: 3366 N. TORREY PINES COURT
STREET 2: SUITE 220
CITY: LA JOLLA
STATE: CA
ZIP: 92037
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Design Therapeutics, Inc.
CENTRAL INDEX KEY: 0001807120
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 823929248
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6005 HIDDEN VALLEY ROAD
STREET 2: SUITE 110
CITY: CARLSBAD
STATE: CA
ZIP: 92011
BUSINESS PHONE: 858-293-4900
MAIL ADDRESS:
STREET 1: 6005 HIDDEN VALLEY ROAD
STREET 2: SUITE 110
CITY: CARLSBAD
STATE: CA
ZIP: 92011
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-09-01
0
0001807120
Design Therapeutics, Inc.
DSGN
0001580787
Shah Pratik
C/O DESIGN THERAPEUTICS, INC.
6005 HIDDEN VALLEY ROAD, SUITE 110
CARLSBAD
CA
92011
1
1
0
0
President, CEO and Chairperson
0
Stock Option (right to buy)
2.48
2023-09-01
4
A
0
1050000
0.00
A
2033-08-31
Common Stock
1050000
1050000
D
Stock Option (right to buy)
2.48
2023-09-01
4
A
0
525000
0.00
A
2033-08-31
Common Stock
525000
525000
D
Stock Option (right to buy)
2.48
2023-09-01
4
A
0
525000
0.00
A
2033-08-31
Common Stock
525000
525000
D
The shares subject to the option will vest as follows: 25% of the shares subject to the option will vest one year following August 25, 2023, and thereafter the balance of the shares will vest in equal monthly installments over the following 36 months.
The shares subject to the option will vest as follows provided that an investigational new drug application for a product candidate for the treatment of Friedrich ataxia ("FA") submitted by the Issuer after September 1, 2023 receives clearance from the U.S. Food and Drug Administration: 25% of the shares subject to the option will vest one year following August 25, 2023, and thereafter the balance of the shares will vest in equal monthly installments over the following 36 months.
The shares subject to the option will vest as follows provided that the Company initiates a Phase 2a clinical trial for a product candidate for the treatment of FA: 25% of the shares subject to the option will vest one year following August 25, 2023, and thereafter the balance of the shares will vest in equal monthly installments over the following 36 months.
/s/ Mustapha Parekh, Attorney-in-Fact
2023-09-05